CR7013A - Nuevos compuestos antiinflamatorios de triazolopiridinas - Google Patents

Nuevos compuestos antiinflamatorios de triazolopiridinas

Info

Publication number: CR7013A
Authority: CR; Costa Rica
Prior art keywords: new; triazolopiridin; inflammatory compounds; present; compounds
Prior art date: 2001-03-09

Application number

CR7013A

Other languages

English (en)

Spanish (es)

Inventor

Anthony Dombroski Mark

Jacob Duplantier Allen

Ruth Laird Elen

Anthony Letavic Michael

Francis Mcclure Kim

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-09

Filing date

2003-06-30

Publication date

2003-11-25

2003-06-30 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-11-25 Publication of CR7013A publication Critical patent/CR7013A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Toxicology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CR7013A 2001-03-09 2003-06-30 Nuevos compuestos antiinflamatorios de triazolopiridinas CR7013A (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US27484001P	2001-03-09	2001-03-09

Publications (1)

Publication Number	Publication Date
CR7013A true CR7013A (es)	2003-11-25

Family

ID=23049813

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR7013A CR7013A (es)	2001-03-09	2003-06-30	Nuevos compuestos antiinflamatorios de triazolopiridinas

Country Status (37)

Country	Link
US (1)	US6696464B2 (is)
EP (1)	EP1370559B1 (is)
JP (1)	JP4130774B2 (is)
KR (1)	KR20030080087A (is)
CN (1)	CN1496366A (is)
AP (1)	AP2002002463A0 (is)
AR (1)	AR036152A1 (is)
AT (1)	ATE323701T1 (is)
BG (1)	BG108133A (is)
BR (1)	BR0207990A (is)
CA (1)	CA2440222C (is)
CR (1)	CR7013A (is)
CZ (1)	CZ20032185A3 (is)
DE (1)	DE60210755T2 (is)
DO (1)	DOP2002000353A (is)
EA (1)	EA200300864A1 (is)
EC (1)	ECSP034762A (is)
EE (1)	EE200300437A (is)
ES (1)	ES2260415T3 (is)
GT (1)	GT200200042A (is)
HR (1)	HRP20030719A2 (is)
HU (1)	HUP0303415A2 (is)
IL (1)	IL156567A0 (is)
IS (1)	IS6858A (is)
MA (1)	MA26991A1 (is)
MX (1)	MXPA03008144A (is)
NO (1)	NO20033969L (is)
NZ (1)	NZ526528A (is)
OA (1)	OA12552A (is)
PA (1)	PA8541001A1 (is)
PE (1)	PE20030010A1 (is)
PL (1)	PL363959A1 (is)
SK (1)	SK10272003A3 (is)
TN (1)	TNSN02022A1 (is)
UY (1)	UY27199A1 (is)
WO (1)	WO2002072579A1 (is)
ZA (1)	ZA200304983B (is)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6372206B1 (en) *	1989-03-02	2002-04-16	University Of Florida	Orally-administered interferon-TAU compositions and methods
US20040077605A1 (en) *	2001-06-20	2004-04-22	Salvati Mark E.	Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (en) *	2000-09-19	2007-11-28	Bristol-Myers Squibb Company	Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en)	2001-02-27	2004-05-06	Salvati Mark E.	Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0124931D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124938D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124939D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124933D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124941D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124934D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124936D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
EP1467979B1 (en) *	2001-12-19	2008-08-13	Bristol-Myers Squibb Company	Fused heterocyclic compounds and analogs thereof modulators of nuclear hormone receptor function
PL212910B1 (pl)	2002-02-12	2012-12-31	Smithkline Beecham Corp	Pochodna nikotynoamidu, srodek farmaceutyczny i zastosowanie pochodnej nikotynoamidu
GB0217757D0 (en)	2002-07-31	2002-09-11	Glaxo Group Ltd	Novel compounds
US7005523B2 (en)	2002-08-30	2006-02-28	Pfizer Inc.	Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US7012143B2 (en)	2002-08-30	2006-03-14	Dombroski Mark A	Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US6949652B2 (en)	2002-08-30	2005-09-27	Pfizer, Inc.	Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
US20040092547A1 (en) *	2002-08-30	2004-05-13	Pfizer Inc	Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7037923B2 (en)	2002-08-30	2006-05-02	Pfizer, Inc.	Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
PA8579601A1 (es)	2002-08-30	2004-05-07	Pfizer Prod Inc	Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
EP1537107A2 (en) *	2002-08-30	2005-06-08	Pfizer Products Inc.	Novel processes and intermediates for preparing triazolo-pyridines
MXPA05008568A (es) *	2003-02-14	2005-11-04	Pfizer Prod Inc	Nuevos compuestos anti-inflamatorios triazolo-piridinas.
CA2517517C (en)	2003-03-03	2012-12-18	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
US7135575B2 (en)	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
PA8595001A1 (es) *	2003-03-04	2004-09-28	Pfizer Prod Inc	Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0308185D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0308201D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0308186D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
AU2004305318A1 (en) *	2003-12-18	2005-07-07	Pfizer Products Inc.	Methods of treating acute inflammation in animals with p38 MAP kinase inhibitors
GB0402143D0 (en) *	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
TWI332003B (en)	2004-01-30	2010-10-21	Lilly Co Eli	Kinase inhibitors
JP2008504294A (ja) *	2004-06-25	2008-02-14	アムジエン・インコーポレーテツド	サイトカイン介在疾患および他の疾患の治療において有用な縮合トリアゾールおよびインダゾール
KR100871535B1 (ko)	2004-08-12	2008-12-05	화이자 인코포레이티드	Ｐ38 ｍａｐ 키나아제 억제제로서의트리아졸로피리딘일설판일 유도체
AU2005273612B2 (en) *	2004-08-12	2010-10-14	Pfizer Inc.	Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
WO2006018735A2 (en) *	2004-08-18	2006-02-23	Pharmacia & Upjohn Company Llc	Triazolopyridine compounds
US20090215817A1 (en) *	2004-08-18	2009-08-27	Pfizer Inc	Novel Triazolopyridine Compounds for the Treatment of Inflammation
US20080051416A1 (en) *	2004-10-05	2008-02-28	Smithkline Beecham Corporation	Novel Compounds
US7572807B2 (en) *	2005-06-09	2009-08-11	Bristol-Myers Squibb Company	Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) *	2005-06-09	2009-08-25	Bristol-Myers Squibb Company	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
GB0512429D0 (en) *	2005-06-17	2005-07-27	Smithkline Beecham Corp	Novel compound
PE20070341A1 (es) *	2005-07-29	2007-04-13	Wyeth Corp	Derivados de pirrol como moduladores del receptor de progesterona
PE20070404A1 (es) *	2005-07-29	2007-05-10	Wyeth Corp	Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
PE20070182A1 (es)	2005-07-29	2007-03-06	Wyeth Corp	Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
SG175599A1 (en)	2006-01-31	2011-11-28	Array Biopharma Inc	Kinase inhibitors and methods of use thereof
EP2057164A1 (en)	2006-08-07	2009-05-13	Incyte Corporation	Triazolotriazines as kinase inhibitors
ES2301380B1 (es)	2006-08-09	2009-06-08	Laboratorios Almirall S.A.	Nuevos derivados de 1,7-naftiridina.
JP2010505855A (ja)	2006-10-06	2010-02-25	アボット・ラボラトリーズ	新規なイミダゾチアゾール類およびイミダゾオキサゾール類
EP3443958A1 (en)	2006-11-22	2019-02-20	Incyte Holdings Corporation	Imidazotriazines and imidazopyrimidines as kinase inhibitors
ES2320955B1 (es)	2007-03-02	2010-03-16	Laboratorios Almirall S.A.	Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es)	2007-04-26	2010-09-23	Laboratorios Almirall S.A.	Nuevos derivados de 4,8-difenilpoliazanaftaleno.
US8188083B2 (en) *	2007-06-28	2012-05-29	Abbott Laboratories	Triazolopyridazines
CA2691448A1 (en) *	2007-08-31	2009-03-05	Dominique Swinnen	Triazolopyridine compounds and their use as ask inhibitors
US8119658B2 (en)	2007-10-01	2012-02-21	Bristol-Myers Squibb Company	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
EP2108641A1 (en)	2008-04-11	2009-10-14	Laboratorios Almirall, S.A.	New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en)	2008-04-28	2009-11-04	Laboratorios Almirall, S.A.	New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
NZ589622A (en)	2008-05-21	2012-10-26	Incyte Corp	Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
US8987251B2 (en)	2008-08-19	2015-03-24	Array Biopharma Inc.	Triazolopyridine compounds as PIM kinase inhibitors
WO2010022081A1 (en)	2008-08-19	2010-02-25	Array Biopharma Inc.	Triazolopyridine compounds as pim kinase inhibitors
TWI496779B (zh)	2008-08-19	2015-08-21	Array Biopharma Inc	作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
US8895550B2 (en)	2008-08-19	2014-11-25	Array Biopharma Inc.	Triazolopyridine compounds as PIM kinase inhibitors
DK2464645T3 (en)	2009-07-27	2017-10-23	Gilead Sciences Inc	CONDENSED, HETEROCYCLIC COMPOUNDS AS IRON CHANNEL MODULATORS
EP2322176A1 (en)	2009-11-11	2011-05-18	Almirall, S.A.	New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
ES2608329T3 (es)	2010-02-03	2017-04-07	Incyte Holdings Corporation	Imidazo[1,2-b][1,2,4]triazinas como inhibidores de c-Met
US8703759B2 (en)	2010-07-02	2014-04-22	Gilead Sciences, Inc.	Fused heterocyclic compounds as ion channel modulators
WO2012065297A1 (en) *	2010-11-16	2012-05-24	Impact Therapeutics, Inc.	3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CN103370316B (zh) *	2010-11-16	2015-06-24	南京英派药业有限公司	作为细胞增殖抑制剂的3-芳基-6-芳基-[1,2,4]三唑并[4,3-a]吡啶及其应用
CN103492377B (zh)	2011-02-25	2016-04-20	阵列生物制药公司	作为pim激酶抑制剂的三唑并吡啶化合物
PL2707361T3 (pl)	2011-05-10	2018-01-31	Gilead Sciences Inc	Skondensowane związki heterocykliczne stosowane jako modulatory kanału sodowego
TWI622583B (zh)	2011-07-01	2018-05-01	基利科學股份有限公司	作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (is)	2011-07-01	2018-04-28
CN105263490B (zh) *	2013-03-14	2018-05-22	基因泰克公司	取代的三唑并吡啶及其使用方法
GB201321742D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
WO2015157955A1 (en) *	2014-04-17	2015-10-22	Abbvie Inc.	Heterocyclic btk inhibit ors
GB201511382D0 (en)	2015-06-29	2015-08-12	Imp Innovations Ltd	Novel compounds and their use in therapy
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
EP3691620B1 (en)	2017-10-05	2022-07-27	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN116514801B (zh) *	2022-01-20	2024-11-08	四川大学	2-苯基-[1,2,4]三唑并[1,5-a]吡啶类化合物、其氮氧化物及用途
CN114504636B (zh) *	2022-01-27	2023-09-26	华南理工大学	一种杏仁油烫伤膏及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US576499A (en) *		1897-02-02		Gas apparatus
US5716972A (en) *	1993-01-13	1998-02-10	Smithkline Beecham Corporation	Pyridyl substituted imidazoles
DE69421624T2 (de)	1993-09-17	2000-07-20	Smithkline Beecham Corp., Philadelphia	Medikamente bindendes protein
IT1269176B (it) *	1994-01-11	1997-03-21	Isagro Srl	Eterobicicli ad attivita' fungicida
US5717100A (en)	1995-10-06	1998-02-10	Merck & Co., Inc.	Substituted imidazoles having anti-cancer and cytokine inhibitory activity
TR199801361T2 (xx)	1996-01-11	1998-10-21	Smithkline Beecham Corporation	Yeni ikameli imidazol bile�imleri.
ZA97175B (en) *	1996-01-11	1997-11-04	Smithkline Beecham Corp	Novel substituted imidazole compounds.
GB9713726D0 (en)	1997-06-30	1997-09-03	Ciba Geigy Ag	Organic compounds
WO1999061440A1 (en)	1998-05-26	1999-12-02	Smithkline Beecham Corporation	Novel substituted imidazole compounds
US6207687B1 (en) *	1998-07-31	2001-03-27	Merck & Co., Inc.	Substituted imidazoles having cytokine inhibitory activity
US6350744B1 (en)	1998-11-20	2002-02-26	Merck & Co., Inc.	Compounds having cytokine inhibitory activity
ES2188280T3 (es)	1998-12-16	2003-06-16	Aventis Pharma Ltd	Acetales heteroaril-ciclicos.
EP1140083A4 (en)	1999-01-08	2004-01-02	Smithkline Beecham Corp	NEW CONNECTIONS
ES2377847T3 (es)	1999-01-13	2012-04-02	Bayer Healthcare Llc	Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
CO5170501A1 (es)	1999-04-14	2002-06-27	Novartis Ag	AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO

2002
- 2002-02-08 AP APAP/P/2002/002463A patent/AP2002002463A0/en unknown
- 2002-02-08 OA OA1200300203A patent/OA12552A/en unknown
- 2002-02-08 BR BR0207990-9A patent/BR0207990A/pt not_active IP Right Cessation
- 2002-02-08 DE DE60210755T patent/DE60210755T2/de not_active Expired - Fee Related
- 2002-02-08 WO PCT/IB2002/000424 patent/WO2002072579A1/en not_active Ceased
- 2002-02-08 CZ CZ20032185A patent/CZ20032185A3/cs unknown
- 2002-02-08 JP JP2002571495A patent/JP4130774B2/ja not_active Expired - Fee Related
- 2002-02-08 PL PL02363959A patent/PL363959A1/xx not_active Application Discontinuation
- 2002-02-08 NZ NZ526528A patent/NZ526528A/en unknown
- 2002-02-08 HU HU0303415A patent/HUP0303415A2/hu unknown
- 2002-02-08 ES ES02710260T patent/ES2260415T3/es not_active Expired - Lifetime
- 2002-02-08 IL IL15656702A patent/IL156567A0/xx unknown
- 2002-02-08 HR HR20030719A patent/HRP20030719A2/hr not_active Application Discontinuation
- 2002-02-08 EP EP02710260A patent/EP1370559B1/en not_active Expired - Lifetime
- 2002-02-08 CA CA002440222A patent/CA2440222C/en not_active Expired - Fee Related
- 2002-02-08 MX MXPA03008144A patent/MXPA03008144A/es active IP Right Grant
- 2002-02-08 EA EA200300864A patent/EA200300864A1/ru unknown
- 2002-02-08 CN CNA028062825A patent/CN1496366A/zh active Pending
- 2002-02-08 AT AT02710260T patent/ATE323701T1/de not_active IP Right Cessation
- 2002-02-08 KR KR10-2003-7011919A patent/KR20030080087A/ko not_active Ceased
- 2002-02-08 EE EEP200300437A patent/EE200300437A/xx unknown
- 2002-02-08 SK SK1027-2003A patent/SK10272003A3/sk unknown
- 2002-03-05 GT GT200200042A patent/GT200200042A/es unknown
- 2002-03-06 DO DO2002000353A patent/DOP2002000353A/es unknown
- 2002-03-07 UY UY27199A patent/UY27199A1/es not_active Application Discontinuation
- 2002-03-07 PE PE2002000182A patent/PE20030010A1/es not_active Application Discontinuation
- 2002-03-07 AR ARP020100826A patent/AR036152A1/es unknown
- 2002-03-08 TN TNTNSN02022A patent/TNSN02022A1/fr unknown
- 2002-03-08 PA PA20028541001A patent/PA8541001A1/es unknown
- 2002-03-11 US US10/094,760 patent/US6696464B2/en not_active Expired - Fee Related
2003
- 2003-06-23 IS IS6858A patent/IS6858A/is unknown
- 2003-06-26 ZA ZA200304983A patent/ZA200304983B/en unknown
- 2003-06-30 CR CR7013A patent/CR7013A/es not_active Application Discontinuation
- 2003-08-07 MA MA27269A patent/MA26991A1/fr unknown
- 2003-08-25 BG BG108133A patent/BG108133A/bg unknown
- 2003-09-08 NO NO20033969A patent/NO20033969L/no not_active Application Discontinuation
- 2003-09-09 EC EC2003004762A patent/ECSP034762A/es unknown

Also Published As

Publication number	Publication date
HUP0303415A2 (hu)	2004-01-28
PE20030010A1 (es)	2003-01-29
GT200200042A (es)	2003-02-11
PA8541001A1 (es)	2003-05-14
AP2002002463A0 (en)	2002-06-30
ES2260415T3 (es)	2006-11-01
IL156567A0 (en)	2004-01-04
EP1370559B1 (en)	2006-04-19
MA26991A1 (fr)	2004-12-20
PL363959A1 (en)	2004-11-29
AR036152A1 (es)	2004-08-18
WO2002072579A1 (en)	2002-09-19
ZA200304983B (en)	2004-06-29
US6696464B2 (en)	2004-02-24
JP2004522799A (ja)	2004-07-29
DE60210755T2 (de)	2006-11-16
IS6858A (is)	2003-06-23
UY27199A1 (es)	2002-10-31
TNSN02022A1 (fr)	2005-12-23
JP4130774B2 (ja)	2008-08-06
NZ526528A (en)	2005-02-25
ECSP034762A (es)	2003-10-28
CA2440222A1 (en)	2002-09-19
OA12552A (en)	2006-06-06
CA2440222C (en)	2008-11-18
MXPA03008144A (es)	2003-12-12
EE200300437A (et)	2004-02-16
NO20033969D0 (no)	2003-09-08
NO20033969L (no)	2003-10-13
DOP2002000353A (es)	2002-10-15
ATE323701T1 (de)	2006-05-15
DE60210755D1 (de)	2006-05-24
EP1370559A1 (en)	2003-12-17
CN1496366A (zh)	2004-05-12
BR0207990A (pt)	2004-04-27
BG108133A (bg)	2004-09-30
HRP20030719A2 (en)	2005-04-30
US20030096838A1 (en)	2003-05-22
SK10272003A3 (sk)	2004-07-07
EA200300864A1 (ru)	2003-12-25
CZ20032185A3 (en)	2004-06-16
KR20030080087A (ko)	2003-10-10

Publication	Publication Date	Title
CR7013A (es)	2003-11-25	Nuevos compuestos antiinflamatorios de triazolopiridinas
PA8540901A1 (es)	2002-10-28	Nuevos compuestos antiinflamatorios de bencimidazol
PA8536001A1 (es)	2002-08-29	Derivados de quinazolona como antagonistas de receptores adrenérgicos alfa-1a/b
AR036598A1 (es)	2004-09-22	Derivados de 4,5-dihidro-1h-pirazol que tienen potente actividad antagonista de cb1
ES2154167A1 (es)	2001-03-16	Aminoderivados ciclicos antagonistas del receptor ccr-3.
NO20005535D0 (no)	2000-11-02	Pyrazol-derivater som P-38 MAP kinase-inhibitorer
ID27124A (id)	2001-03-01	Penghambat kinase bisiklik
IS6658A (is)	2002-12-17	Ný efnasambönd
PT1263725E (pt)	2005-02-28	Novos compostos
AR032136A1 (es)	2003-10-29	Compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas
ECSP066541A (es)	2006-12-20	Nuevos derivados de piridazin-3(2h)-ona
AR004219A1 (es)	1998-11-04	Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios
BR0014225A (pt)	2002-05-21	Derivados de pirazol
CO5070716A1 (es)	2001-08-28	Composiciones liquidas para la limpieza de superficies duras las cuales contienen un ingrediente antienmugrante
ATE425142T1 (de)	2009-03-15	Inhibitoren von c-jun n-terminal kinasen (jnk)
AR029942A1 (es)	2003-07-23	Compuestos derivados de 1,3-dihidro-2h-indol-2-ona, su utilizacion, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden, medicamentos constituidos por dichos compuestos y compuestos intermediarios
MX9602979A (es)	1998-01-31	Compuestos heterociclicos terapeuticos.
ES2167021T3 (es)	2002-05-01	Derivados de acido 4-bifenil-4-hidroxibutirico sustituidos como inhibidores de metaloproteasa de matriz.
DE60208694D1 (de)	2006-04-06	Piperidinylmorpholinylderivate als modulatoren der aktivität des chemokinrezeptors
ES2112483T3 (es)	1998-04-01	4-aril-4-hidroxi-tetrahidropiranos y 3-aril-3-hidroxi-tetrahidrofuranos como inhibidores de 5-lipoxigenasa.
AR029468A1 (es)	2003-07-02	Derivados de aminoacidos n-mercaptoacilados, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
UY27133A1 (es)	2002-07-31	11beta-halogenesteroides, su obtención y uso para la preparación de medicamentos y preparados farmacéuticos que contienen 11 beta-halogenesteroides
ES2183500T3 (es)	2003-03-16	Nuevos compuestos y composiciones farmaceuticas que los contienen.
SE0403117D0 (sv)	2004-12-21	New compounds 1
AR130892A1 (es)	2025-01-29	Inhibidores de mk2 y usos de los mismos

Legal Events

Date	Code	Title	Description
2006-09-28	FA	Abandonment or withdrawal (granting procedure)